 RESEARCH TRIANGLE PARK, N.C., Aug. 10, 2021 GLOBE NEWSWIRE -- BioCryst Pharmaceuticals, Inc. Nasdaq: BCRX announced today that it has withdrawn its proposed public offering. With our strong balance sheet, and increasing revenues from ORLADEYO berotralstat, we believe that current market conditions are not conducive to an offering on terms that would be in the best interests of our current stockholders. We are well capitalized, with cash, cash equivalents, restricted cash and investments of 222.8 million as of June 30, 2021. Based on our expectations for revenue, operating expenses, and our option to access an additional 75 million from our existing credit facility, we believe our current cash runway takes us into 2023. 